Racial Gap in Breast Cancer Genetic Testing
Black Women Less Likely Than Whites to Get Counseling for Genetic Screening
April 12, 2005 -- Black women are less likely than whites to get counseling for BRCA1 and BRCA2 gene mutations screening. The mutations are linked to increased breast cancer risk.
"White women have almost five times the odds of undergoing BRCA1/2 counseling as African-American women," write Katrina Armstrong, MD, and colleagues in The Journal of the American Medical Association.
The reasons for the racial gap aren't clear. Until the differences are addressed, "the benefit of predictive gene testing will not be fully realized," Armstrong writes. Testing provides information about breast cancer risks that effects decisions about treatment. In addition, it allows other family members to define their own risk, write the authors.
About the Test
BRCA1 and BRCA2 genetic testing is done through a blood test. The testing in at-risk women helps in cancer prevention. It's used for women with a family history that suggests a higher risk of breast cancer.
The results don't mean that a woman definitely will or won't get breast cancer. Instead, it gauges her genetic risks of the disease. The test does not screen for breast cancer itself.
Getting the results can take several weeks. Understandably, the decision and process of getting tested can be emotional. Counseling is strongly encouraged before and after screening to help patients understand the test and weigh their options.
Breast cancer is women's most common cancer, apart from skin cancer. It's second only to lung cancer in women's cancer deaths, says the American Cancer Society.
More white women are diagnosed with breast cancer, but black women who are diagnosed are more likely to be younger, have more aggressive cancers, and are more likely to die of it.
How do the BRCA genes play in? While the mutations are rare in the general population, "Women with a BRCA1/2 mutation have a lifetime breast cancer risk of 50%-85% and a lifetime ovarian cancer risk of 14%-40%," says Armstrong's study.
Who Gets Genetic Testing, Who Doesn't
Armstrong's study included about 400 women enrolled in a large Philadelphia health care system. All had at least one first- or second-degree relative with breast or ovarian cancer, but they hadn't had those diseases themselves.